Newsfeeds Archive - Page 6 of 461

1 minute read

AbbVie’s Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients

June 6, 1:02 PM

AbbVie announced Phase 2 PICCOLO trial results for Elahere in heavily pre-treated ovarian cancer patients. The trial achieved a 51.9% objective response rate.

ABBV

2 minute read

Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released

By Vandana Singh

June 6, 12:43 PM

4D Molecular Therapeutics shares interim data from the 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease.

FDMT

2 minute read

Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?

By Vandana Singh

June 6, 12:16 PM

Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was well-tolerated.

BMY

1 minute read

Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal

By Vandana Singh

June 6, 12:13 PM

Cycle Pharmaceuticals wants to acquire Vanda Pharmaceuticals for $8 per share, or $466 million. Cycle focuses on rare neurological conditions.

VNDA

2 minute read

Eli Lilly’s Alzheimer’s Drug, Donanemab Faces FDA’s Adcomm Vote Next Week On Data, Risk Profile

By Vandana Singh

June 6, 12:07 PM

The FDA's advisory committee will review Eli Lilly's Phase 3 study on donanemab for Alzheimer's disease on June 10. This review assesses the drug's benefit-risk profile based on significant efficacy results in cognition and daily function.

LLY

2 minute read

FDA Selects Moderna’s Rare Disease Candidate For Accelerated Development Program

By Vandana Singh

June 6, 9:59 AM

Moderna's mRNA-370 has been selected for the FDA's START program to accelerate rare disease therapeutics, targeting a 2024 pivotal study.

MRNA

2 minute read

What’s Going On With Sagimet Biosciences Stock On Thursday?

By Vandana Singh

June 6, 9:52 AM

Sagimet Biosciences shared promising data from its FASCINATE-2 Phase 2b trial of denifanstat at the EASL Congress.

SGMT

2 minute read

Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal

By Vandana Singh

June 5, 3:26 PM

Amgen announced Phase 3 trial results for Uplizna for IgG4-related disease, achieving an 87% reduction in flare risk. All key secondary endpoints were met with no new safety signals.

AMGN

2 minute read

Medtronic Recalls Some Versions Of Software Used For Cranial Surgery

By Vandana Singh

June 5, 3:23 PM

Medtronic is recalling specific StealthStation S8 application versions due to a serious software error affecting surgical navigation displays. Medtronic is providing a free software update to fix the problem.

MDT

2 minute read

What’s Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?

By Vandana Singh

June 5, 3:17 PM

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment. Further trials needed to confirm efficacy and safety.

AKRO